YS Biopharma Co Ltd
NASDAQ:LSB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ovaro Kiinteistosijoitus Oyj
OMXH:OVARO
|
FI |
YS Biopharma Co Ltd
Accrued Liabilities
YS Biopharma Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
YS Biopharma Co Ltd
NASDAQ:LSB
|
Accrued Liabilities
¥275.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥3.5B
|
CAGR 3-Years
44%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Accrued Liabilities
¥327.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Accrued Liabilities
¥137.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
YS Biopharma Co Ltd
Glance View
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
See Also
What is YS Biopharma Co Ltd's Accrued Liabilities?
Accrued Liabilities
275.5m
CNY
Based on the financial report for Mar 31, 2025, YS Biopharma Co Ltd's Accrued Liabilities amounts to 275.5m CNY.
What is YS Biopharma Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
7%
Over the last year, the Accrued Liabilities growth was -2%. The average annual Accrued Liabilities growth rates for YS Biopharma Co Ltd have been 7% over the past three years .
